Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US-9757443-B2 · Sep 12, 2017 · US
Neisseria meningitidis composition and methods thereof
US10550159B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10550159-B2 |
| Application number | US-201816208347-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 3, 2018 |
| Priority date | Mar 9, 2012 |
| Publication date | Feb 4, 2020 |
| Grant date | Feb 4, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of eliciting an immune response against Neisseria meningitidis comprising administering to a mammal an effective amount of a composition comprising at least two polypeptides selected from the group consisting of: (a) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71; (b) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 77; (c) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 55; (d) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 68; and (e) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66, wherein the composition comprises aluminum. 2. The method according to claim 1 , wherein the composition comprises (a) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71 and (b) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 77. 3. The method according to claim 1 , wherein the composition comprises (a) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71 and (b) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 55. 4. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71 and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 68. 5. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71 and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66. 6. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 55 and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66. 7. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66 and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 68. 8. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 55; a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66; and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 68. 9. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup A. 10. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup C. 11. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup W135. 12. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup Y. 13. The method according to claim 1 , further comprising administering to the mammal at least two immunogenic conjugates selected from: a) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup A b) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup C c) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup W135; and a) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup Y. 14. The method according to claim 1 , further comprising administering to the mammal at least three conjugates selected from: a) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup A b) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup C c) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup W135; and d) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup Y. 15. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup A; an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup C; an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup W135; and an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup Y.
Assignees
Inventors
Classifications
Inorganic adjuvants · CPC title
Multivalent vaccine · CPC title
raising an immune response against a target which is not the antigen used for immunisation · CPC title
Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title
Neisseria · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10550159B2 cover?
- In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a mening…
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification C07K14/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).